Study Summary
This trial looks at whether psilocybin, a compound found in some mushrooms, can help relieve symptoms of OCD. They will also study what effects psilocybin has on the brain.
- Obsessive-Compulsive Disorder
Treatment Effectiveness
Effectiveness Progress
Study Objectives
4 Primary · 36 Secondary · Reporting Duration: Baseline, 48 hours post-drug, weeks: 1, 2, 4, 12 post-drug
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Psilocybin
1 of 2
Niacin
1 of 2
Experimental Treatment
Non-Treatment Group
30 Total Participants · 2 Treatment Groups
Primary Treatment: Psilocybin (0.25mg/kg) · Has Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 21 - 65 · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
New York | 23.4% |
Connecticut | 19.1% |
New Jersey | 10.6% |
Other | 46.8% |
How old are they?
18 - 65 | 97.6% |
< 18 | 2.4% |
What site did they apply to?
Connecticut Mental Health Center | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 97.9% |
Did not meet criteria | 2.1% |
Why did patients apply to this trial?
- "Promise of psylocibin in OCD"
- "The quality of my life is very poor."
- "I was diagnosed with OCD over 12 years ago. No medications have worked. I am looking for treatment."
How many prior treatments have patients received?
0 | 33.3% |
1 | 33.3% |
3+ | 33.3% |
What questions have other patients asked about this trial?
- "I have had panic attacks; severe as a teenager, infrequent as an adult. If one should experience such an experience, what safeguards are in place to mitigate severity, if panic occurs, during trial?"
How responsive is this trial?
Most responsive sites:
- Connecticut Mental Health Center: < 24 hours
Average response time
- < 2 Days
Typically responds via
100.0% | |
- Carhart-Harris, Robin L., David Erritzoe, Tim Williams, James M. Stone, Laurence J. Reed, Alessandro Colasanti, Robin J. Tyacke, et al.. 2012. “Neural Correlates of the Psychedelic State as Determined by Fmri Studies with Psilocybin”. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1119598109.
- Moreno, Francisco A., Christopher B. Wiegand, E. Keolani Taitano, and Pedro L. Delgado. 2006. “Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients with Obsessive-compulsive Disorder”. The Journal of Clinical Psychiatry. Physicians Postgraduate Press, Inc. doi:10.4088/jcp.v67n1110.
- Griffiths, Roland R, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, and Margaret A Klinedinst. 2016. “Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-threatening Cancer: A Randomized Double-blind Trial”. Journal of Psychopharmacology. SAGE Publications. doi:10.1177/0269881116675513.
- Ross, Stephen, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, et al.. 2016. “Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with Life-threatening Cancer: A Randomized Controlled Trial”. Journal of Psychopharmacology. SAGE Publications. doi:10.1177/0269881116675512.
- Ross, Stephen, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, et al.. 2016. “Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with Life-threatening Cancer: A Randomized Controlled Trial”. Journal of Psychopharmacology. SAGE Publications. doi:10.1177/0269881116675512.
- Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513.
- Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512.
- Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 Nov;67(11):1735-40. doi: 10.4088/jcp.v67n1110.
- Benjamin Kelmendi, MD 2018. "Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03356483.
Frequently Asked Questions
What risks are associated with a 0.25mg/kg dosage of Psilocybin?
"The safety of Psilocybin (0.25mg/kg) is rated a 1, as this clinical trial falls into the Phase 1 stage, meaning there is limited data confirming its efficacy and minimal evidence to suggest it is safe for human consumption." - Anonymous Online Contributor
How many participants are being accepted into this experiment?
"Affirmative. According to the clinicaltrials.gov database, this trial is actively recruiting participants and has been since November 13th 2018; its status was last updated on December 7th 2021. Currently, 30 patients are being sought out over 1 location." - Anonymous Online Contributor
Who meets the criteria to join this medical experiment?
"In order to be eligible for this clinical trial, candidates must have an OCD diagnosis and fall between 21-65 years old. Approximately 30 individuals are needed in total." - Anonymous Online Contributor
Is the enrollment criterion for this research trial restricted to individuals aged 25 or younger?
"The entry qualifications for this medical trial stipulate that potential participants must be 21 or older, while the upper age limit is 65." - Anonymous Online Contributor
What medical conditions has research shown Psilocybin (0.25mg/kg) to be most effective in treating?
"Psilocybin (0.25mg/kg) is a reliable option for treating high cardiovascular risk and other issues like dyslipidemia, pancreatitis risks, and lipidemia." - Anonymous Online Contributor
Are there vacancies for eligible participants in this clinical trial?
"Clinicaltrials.gov records indicate that this medical trial is open to recruitment and was initially posted on November 13th 2018, with the latest update occurring on December 7th 2021." - Anonymous Online Contributor